Cargando…

Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience

SIMPLE SUMMARY: KRAS gene mutations are among the most common oncogenic lesions in NSCLC patients. For many years, they were considered “incurable”. This is now changing and therapeutic options are available for NSCLC patients with mutated KRAS. It is likely that the effectiveness of immunotherapy i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chmielewska, Izabela, Krawczyk, Paweł, Grenda, Anna, Wójcik-Superczyńska, Magdalena, Krzyżanowska, Natalia, Gil, Michał, Milanowski, Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378665/ https://www.ncbi.nlm.nih.gov/pubmed/37509393 http://dx.doi.org/10.3390/cancers15143732

Ejemplares similares

In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review
por: Rekowska, Anna, et al.
Publicado: (2022)

Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019)

The efficacy of T790M mutation testing in liquid biopsy—Real clinic data
por: Krawczyk, Paweł, et al.
Publicado: (2022)

Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in BRAF and p.R461* in NF1 Genes—A Case Report with Literature Review
por: Grenda, Anna, et al.
Publicado: (2023)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2022)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2022)

Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
por: Grenda, Anna, et al.
Publicado: (2022)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
por: Terlecka, Paulina, et al.
Publicado: (2021)

Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non‐small cell lung cancer patients
por: Grenda, Anna, et al.
Publicado: (2019)

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
por: Krukowska, Kinga, et al.
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
por: El Osta, Badi
Publicado: (2023)

Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”
por: Nagasaka, Misako, et al.
Publicado: (2023)

Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients
por: Nicoś, Marcin, et al.
Publicado: (2020)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
por: Cefalì, Marco, et al.
Publicado: (2022)

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
por: Manson, Guillaume, et al.
Publicado: (2019)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
por: Grenda, Anna, et al.
Publicado: (2020)

Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2021)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Drugging the Undruggable Trypanosoma brucei Monothiol Glutaredoxin 1
por: Favaro, Annagiulia, et al.
Publicado: (2023)

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2015)

Therapeutic targeting of “undruggable” MYC
por: Llombart, Victor, et al.
Publicado: (2021)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_947bi6v0q9irbs3itk7k07fkn8